134 related articles for article (PubMed ID: 21745658)
41. [Construction and expression of eukaryotic expression vector of human 4-1BB ligand gene in tumor cells and its antitumor activity in vitro].
Lu K; Wu JY; Li BQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jun; 23(6):511-4. PubMed ID: 17553345
[TBL] [Abstract][Full Text] [Related]
42. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells.
Krause P; Bruckner M; Uermösi C; Singer E; Groettrup M; Legler DF
Blood; 2009 Mar; 113(11):2451-60. PubMed ID: 19029446
[TBL] [Abstract][Full Text] [Related]
43. Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.
Mbanwi AN; Lin GHY; Wang KC; Watts TH
J Immunol Methods; 2017 Nov; 450():81-89. PubMed ID: 28789924
[TBL] [Abstract][Full Text] [Related]
44. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.
Macdonald DC; Hotblack A; Akbar S; Britton G; Collins MK; Rosenberg WC
J Immunol; 2014 Nov; 193(10):5056-64. PubMed ID: 25305314
[TBL] [Abstract][Full Text] [Related]
45. Changes in lymphocytes' telomerase activity by 4-1BB costimulation.
Ahmad HT; Mansooreh J; Fereshteh M; Mojtaba H
J Cancer Res Ther; 2014; 10(4):998-1003. PubMed ID: 25579543
[TBL] [Abstract][Full Text] [Related]
46. Effects of epidermal growth factor receptor fusion protein on the cytotoxic activity of SOCS1-silenced dendritic cells in vitro.
Jiang Q; Wang X; Qian M; Chen D; Xu Y
Oncol Rep; 2018 Mar; 39(3):1306-1312. PubMed ID: 29286121
[TBL] [Abstract][Full Text] [Related]
47. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.
Daniel-Meshulam I; Horovitz-Fried M; Cohen CJ
Int J Cancer; 2013 Dec; 133(12):2903-13. PubMed ID: 23754772
[TBL] [Abstract][Full Text] [Related]
48. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
49. Construction of a recombinant adenovirus co-expressing truncated human prostate-specific membrane antigen and mouse 4-1BBL genes and its effect on dendritic cells.
Weng X; Kuang Y; Liu X; Chen Z; Zhu H; Chen H; Jiang B; Shen H
Braz J Med Biol Res; 2011 Mar; 44(3):186-92. PubMed ID: 21243315
[TBL] [Abstract][Full Text] [Related]
50. Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma.
Li G; Wu X; Zhang F; Li X; Sun B; Yu Y; Yin A; Deng L; Yin J; Wang X
J Cancer Res Clin Oncol; 2011 Apr; 137(4):695-703. PubMed ID: 20563597
[TBL] [Abstract][Full Text] [Related]
51. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of Vγ9Vδ2 T cells in low levels of IL-2.
Cho HW; Kim SY; Sohn DH; Lee MJ; Park MY; Sohn HJ; Cho HI; Kim TG
J Leukoc Biol; 2016 Apr; 99(4):521-9. PubMed ID: 26561569
[TBL] [Abstract][Full Text] [Related]
52. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
53. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
54. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway.
Melero I; Bach N; Hellström KE; Aruffo A; Mittler RS; Chen L
Eur J Immunol; 1998 Mar; 28(3):1116-21. PubMed ID: 9541607
[TBL] [Abstract][Full Text] [Related]
55. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.
Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B
Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890
[TBL] [Abstract][Full Text] [Related]
56. Tumor expression of 4-1BB ligand sustains tumor lytic T cells.
Zhang H; Merchant MS; Chua KS; Khanna C; Helman LJ; Telford B; Ward Y; Summers J; Toretsky J; Thomas EK; June CH; Mackall CL
Cancer Biol Ther; 2003; 2(5):579-86. PubMed ID: 14614331
[TBL] [Abstract][Full Text] [Related]
57. Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.
Kumari A; Garnett-Benson C
BMC Res Notes; 2016 Feb; 9():92. PubMed ID: 26872462
[TBL] [Abstract][Full Text] [Related]
58. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.
Salih HR; Kosowski SG; Haluska VF; Starling GC; Loo DT; Lee F; Aruffo AA; Trail PA; Kiener PA
J Immunol; 2000 Sep; 165(5):2903-10. PubMed ID: 10946324
[TBL] [Abstract][Full Text] [Related]
59. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
[TBL] [Abstract][Full Text] [Related]
60. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.
Wang R; Freywald A; Chen Y; Xu J; Tan X; Xiang J
Cell Mol Immunol; 2015 Jul; 12(4):456-65. PubMed ID: 25195511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
